CoChat

Evaluation of drug treatment in irritable bowel syndrome

Open access
Talley, Nicholas J. · 2003 · British Journal of Clinical Pharmacology
Cited by 78

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The irritable bowel syndrome (IBS) remains a therapeutic challenge in part because of the limited understanding of the pathophysiology. The placebo response rate varies in randomized controlled trials from 20 to 70%, and can persist for up to at least 1 year. It is contentious whether dietary fibre and bulking agents relieve the symptoms of IBS; constipation probably improves. Anticholinergic and antispasmodic agents are of questionable benefit in IBS despite positive meta‐analyses of poor quality trials. A meta‐analysis concluded that the tricyclic antidepressants were superior to placebo in IBS, although the individual trial results were variable. Selective serotonin reuptake inhibitors are of uncertain benefit. Laxatives are used for constipation but probably poorly control the IBS symptom complex. Loperamide is superior to placebo in improvement of diarrhoea but not abdominal pain in IBS. Tegaserod is a well‐ tolerated aminoguanidine indole derivative of serotonin that is a partial 5HT 4–receptor agonist with prokinetic properties; a therapeutic gain over placebo of 5% to 15% has been observed in constipation‐predominant IBS in females. Alosetron is a 5HT 3‐receptor antagonist that is efficacious in females with diarrhoea‐predominant IBS, with a 12% to 17% therapeutic gain; the risk of ischaemic colitis is 1 in 350, with very severe constipation occurring in about 1 in 1000. Optimizing study design remains a challenge in IBS. New visceral analgesic and motility modifying agents, as well as anti‐inflammatory agents are in trials, and hopefully additional efficacious therapeutic options for patients with IBS will soon emerge.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.2003.01966.x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 78

Metadata

Authors
Talley, N. J.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2003-09-12
Volume
56
Issue
4
Pages
362-369
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1566813966
Cited by
78
References
11
FWCI
8.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of drug treatment in irritable bowel syndrome. https://app.cochat.ai/papers/10.1046/j.1365-2125.2003.01966.x
The paper
Talley, N. J. (2003). Evaluation of drug treatment in irritable bowel syndrome. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2003.01966.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.